From Bench to Bedside: the Past, Present and Future of IL-21 Immunotherapy

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jun 20

PMID 38900341

Authors

Austin M Kim

Lei Zhao

Tej R Patel

Colin J Bailey

Qian Bai

Mark R Wakefield

Yujiang Fang

Affiliations

Soon will be listed here.

Abstract

As immunotherapy gains momentum as a promising approach for treating several types of cancer, IL-21 has emerged as the latest discovery within the γ chain cytokine family, known for its decisive effects on innate and adaptive immunity and immunopathology. Through the modulation of immune cells, IL-21 has demonstrated significant anti-tumor effects in preclinical studies. The potential of IL-21 in cancer treatment has been explored in phase I and II clinical trials, where it has been utilized both as monotherapy and in combination with other drug agents. Further investigation, alongside larger studies, is necessary before final evaluation and application of IL-21 as immunotherapy. This review aims to summarize these pre-clinical and clinical studies and to discuss the possible future directions of IL-21 immunotherapy development. Such a study may be helpful to accelerate the process of clinical application for IL21 immunotherapy.

References

Santegoets S, Turksma A, Powell Jr D, Hooijberg E, de Gruijl T . IL-21 in cancer immunotherapy: At the right place at the right time. Oncoimmunology. 2013; 2(6):e24522. PMC: 3716748. DOI: 10.4161/onci.24522. View

Leonard W, Lin J, OShea J . The γ Family of Cytokines: Basic Biology to Therapeutic Ramifications. Immunity. 2019; 50(4):832-850. DOI: 10.1016/j.immuni.2019.03.028. View

Noguchi M, Yi H, Rosenblatt H, Filipovich A, Adelstein S, Modi W . Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993; 73(1):147-57. DOI: 10.1016/0092-8674(93)90167-o. View

Habib T, Senadheera S, Weinberg K, Kaushansky K . The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry. 2002; 41(27):8725-31. DOI: 10.1021/bi0202023. View

Berglund L, Avery D, Ma C, Moens L, Deenick E, Bustamante J . IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood. 2013; 122(24):3940-50. PMC: 3854113. DOI: 10.1182/blood-2013-06-506865. View

Leonard W, Wan C . IL-21 Signaling in Immunity. F1000Res. 2016; 5. PMC: 4770986. DOI: 10.12688/f1000research.7634.1. View

Davis M, Zhu Z, Hansen D, Bai Q, Fang Y . The role of IL-21 in immunity and cancer. Cancer Lett. 2015; 358(2):107-114. DOI: 10.1016/j.canlet.2014.12.047. View

Tanabe Y, Nishibori T, Su L, Arduini R, Baker D, David M . Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol. 2005; 174(2):609-13. DOI: 10.4049/jimmunol.174.2.609. View

Matsuoka T, Yashiro M . The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel). 2014; 6(3):1441-63. PMC: 4190549. DOI: 10.3390/cancers6031441. View

10.

Waskiewicz A, Cooper J . Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol. 1995; 7(6):798-805. DOI: 10.1016/0955-0674(95)80063-8. View

11.

Chabab G, Bonnefoy N, Lafont V . IL-21 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1240:73-82. DOI: 10.1007/978-3-030-38315-2_6. View

12.

Ferrari-Lacraz S, Chicheportiche R, Schneiter G, Molnarfi N, Villard J, Dayer J . IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol. 2008; 20(8):1009-18. DOI: 10.1093/intimm/dxn059. View

13.

Deenick E, Avery D, Chan A, Berglund L, Ives M, Moens L . Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med. 2013; 210(12):2739-53. PMC: 3832925. DOI: 10.1084/jem.20130323. View

14.

Jiang T, Zhou C, Ren S . Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016; 5(6):e1163462. PMC: 4938354. DOI: 10.1080/2162402X.2016.1163462. View

15.

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

16.

Li Y, Yee C . IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2007; 111(1):229-35. PMC: 2200808. DOI: 10.1182/blood-2007-05-089375. View

17.

Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

18.

Moudgil K, Choubey D . Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011; 31(10):695-703. PMC: 3189547. DOI: 10.1089/jir.2011.0065. View

19.

Ma H, Whitters M, Konz R, Senices M, Young D, Grusby M . IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol. 2003; 171(2):608-15. DOI: 10.4049/jimmunol.171.2.608. View

20.

Ugai S, Shimozato O, Yu L, Wang Y, Kawamura K, Yamamoto H . Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 2003; 10(10):771-8. DOI: 10.1038/sj.cgt.7700630. View